On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform acro ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a company-funded study. The study was ...

Mana.bio, a biotechnology company leveraging artificial intelligence (AI) and nanotechnology for targeted RNA delivery, today announced three poster presentations at the American Society of Gene & ...